PHK
ALXN

Point72 Hong Kong’s Alexion Pharmaceuticals ALXN Stock Holding History

Point72 Hong Kong’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,100
Closed -$202K – 2619
2021
Q2 		$202K Sell
1,100
-9,600
-90% -$1.65M 0.01% 1151
2021
Q1 		$1.64M Buy
10,700
+6,900
+182% +$1.07M 0.06% 475
2020
Q4 		$594K Buy
+3,800
New +$488K 0.03% 652

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Point72 Hong Kong's ALXN Position: Q3 2021 in Review

Point72 Hong Kong sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 480 shares — an estimated $88K sold.

Point72 Hong Kong first reported a position in ALXN in Q1 2015 and held it in 12 quarters. The position peaked at $1.08M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Point72 Hong Kong reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 480 Alexion Pharmaceuticals shares in Q3 2021, an estimated $88K.
  • Point72 Hong Kong first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Point72 Hong Kong's Alexion Pharmaceuticals position peaked at $1.08M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.